Matthew Lang - 10 Aug 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Business Officer
Signature
/s/ Matthew Lang
Issuer symbol
LYEL
Transactions as of
10 Aug 2023
Net transactions value
$0
Form type
4
Filing time
11 Aug 2023, 16:24:38 UTC
Previous filing
20 Jul 2023
Next filing
13 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +2,250,000 $0.000000 2,250,000 10 Aug 2023 Common Stock 2,250,000 $2.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares shall vest on July 1, 2024, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.